These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15207762)

  • 21. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age.
    Plotkin H; Rauch F; Bishop NJ; Montpetit K; Ruck-Gibis J; Travers R; Glorieux FH
    J Clin Endocrinol Metab; 2000 May; 85(5):1846-50. PubMed ID: 10843163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decrease of serum alkaline phosphatase after three cycles of pamidronate disodium in children with severe osteogenesis imperfecta.
    Cabral de Menezes Filho H; Rodrigues JM; Radonsky V; Della Manna T; Kuperman H; Steinmetz L; Dichtchekenian V; Damiani D; Setian N
    Horm Res; 2007; 68 Suppl 5():207-8. PubMed ID: 18174750
    [No Abstract]   [Full Text] [Related]  

  • 23. Osteogenesis imperfecta, current and future medical treatment.
    Rauch F; Glorieux FH
    Am J Med Genet C Semin Med Genet; 2005 Nov; 139C(1):31-7. PubMed ID: 16278881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long?
    Rauch F; Glorieux FH
    Ann Med; 2005; 37(4):295-302. PubMed ID: 16019729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism.
    Rauch F; Plotkin H; Travers R; Zeitlin L; Glorieux FH
    J Clin Endocrinol Metab; 2003 Mar; 88(3):986-92. PubMed ID: 12629073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates.
    Malmgren B; Aström E; Söderhäll S
    J Oral Pathol Med; 2008 Apr; 37(4):196-200. PubMed ID: 18321345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alendronate treatment in children with osteogenesis imperfecta.
    Akcay T; Turan S; Guran T; Bereket A
    Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases.
    Munns CF; Rauch F; Ward L; Glorieux FH
    J Bone Miner Res; 2004 Oct; 19(10):1742-5. PubMed ID: 15355570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclic intravenous pamidronate for an infant with osteogenesis imperfecta type II.
    Fukahori K; Nirei J; Yamawaki K; Nagasaki K
    BMJ Case Rep; 2023 May; 16(5):. PubMed ID: 37188488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclic intravenous pamidronate in a very low-birthweight infant with osteogenesis imperfecta.
    Eto S; Hada S; Fukuhara R; Nishimura G; Takagi M
    Pediatr Int; 2018 May; 60(5):485-486. PubMed ID: 29700899
    [No Abstract]   [Full Text] [Related]  

  • 31. Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta.
    Montpetit K; Plotkin H; Rauch F; Bilodeau N; Cloutier S; Rabzel M; Glorieux FH
    Pediatrics; 2003 May; 111(5 Pt 1):e601-3. PubMed ID: 12728117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decrease in serum FGF23 levels after intravenous infusion of pamidronate in patients with osteogenesis imperfecta.
    Kitaoka T; Namba N; Miura K; Kubota T; Ohata Y; Fujiwara M; Hirai H; Yamamoto T; Ozono K
    J Bone Miner Metab; 2011 Sep; 29(5):598-605. PubMed ID: 21344299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta.
    Amarasena S; Lekamwasam S; Jayawardena P
    Ceylon Med J; 2005 Sep; 50(3):137-8. PubMed ID: 16252586
    [No Abstract]   [Full Text] [Related]  

  • 34. Pamidronate treatment of severe osteogenesis imperfecta in a newborn infant.
    Chien YH; Chu SY; Hsu CC; Hwu WL
    J Inherit Metab Dis; 2002 Nov; 25(7):593-5. PubMed ID: 12638943
    [No Abstract]   [Full Text] [Related]  

  • 35. Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.
    de Lemos ML; Taylor SC; Barnett JB; Hu F; Levin A; Moravan V; O'Reilly SE
    J Oncol Pharm Pract; 2006 Dec; 12(4):193-9. PubMed ID: 17156591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pulmonary function tests in an infant with osteogenesis imperfecta and early biphosphonate treatment.
    Rugolotto S; Monti E; Carli M; Pietrobelli A; Antoniazzi F; Tato L
    Acta Paediatr; 2007 Dec; 96(12):1856-7. PubMed ID: 18001342
    [No Abstract]   [Full Text] [Related]  

  • 37. Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases.
    Chan B; Zacharin M
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2017-20. PubMed ID: 16551739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Osteogenesis imperfecta and intravenous pamidronate.
    Banerjee I; Shortland GJ; Evans WD; Gregory JW
    Arch Dis Child; 2002 Dec; 87(6):562-3. PubMed ID: 12456578
    [No Abstract]   [Full Text] [Related]  

  • 39. Intravenous pamidronate treatment in osteogenesis imperfecta.
    Fujiwara I; Ogawa E; Igarashi Y; Ohba M; Asanuma A
    Eur J Pediatr; 1998 Mar; 157(3):261-2. PubMed ID: 9537501
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta.
    Kamoun-Goldrat A; Ginisty D; Le Merrer M
    Eur J Oral Sci; 2008 Jun; 116(3):195-8. PubMed ID: 18471236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.